Thermo Fisher Scientific Inc. (NYSE:TMO) is L. Roy Papp & Associates LLP’s 8th Largest Position

L. Roy Papp & Associates LLP lifted its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 50,278 shares of the medical research company’s stock after purchasing an additional 313 shares during the quarter. Thermo Fisher Scientific comprises about 3.3% of L. Roy Papp & Associates LLP’s holdings, making the stock its 8th biggest holding. L. Roy Papp & Associates LLP’s holdings in Thermo Fisher Scientific were worth $26,687,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of the company. ERn Financial LLC grew its holdings in shares of Thermo Fisher Scientific by 3.6% in the fourth quarter. ERn Financial LLC now owns 1,790 shares of the medical research company’s stock valued at $975,000 after purchasing an additional 62 shares during the period. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH boosted its stake in Thermo Fisher Scientific by 0.4% during the fourth quarter. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH now owns 24,618 shares of the medical research company’s stock worth $13,067,000 after buying an additional 88 shares during the period. Manning & Napier Group LLC boosted its stake in Thermo Fisher Scientific by 1.7% during the fourth quarter. Manning & Napier Group LLC now owns 145,447 shares of the medical research company’s stock worth $77,202,000 after buying an additional 2,453 shares during the period. New Capital Management LP boosted its stake in Thermo Fisher Scientific by 10.9% during the fourth quarter. New Capital Management LP now owns 480 shares of the medical research company’s stock worth $255,000 after buying an additional 47 shares during the period. Finally, James Hambro & Partners boosted its stake in Thermo Fisher Scientific by 9.7% during the fourth quarter. James Hambro & Partners now owns 187,893 shares of the medical research company’s stock worth $99,817,000 after buying an additional 16,594 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In other news, Director Debora L. Spar sold 164 shares of the firm’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the transaction, the director now directly owns 1,207 shares in the company, valued at $660,192.79. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, SVP Michael A. Boxer sold 14,566 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the transaction, the senior vice president now directly owns 12,901 shares in the company, valued at $7,250,362. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Debora L. Spar sold 164 shares of Thermo Fisher Scientific stock in a transaction on Monday, February 12th. The shares were sold at an average price of $546.97, for a total transaction of $89,703.08. Following the completion of the transaction, the director now owns 1,207 shares in the company, valued at $660,192.79. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 50,277 shares of company stock worth $28,513,384. Insiders own 0.32% of the company’s stock.

Thermo Fisher Scientific Stock Up 0.3 %

Thermo Fisher Scientific stock traded up $1.84 during mid-day trading on Friday, hitting $581.21. The company had a trading volume of 1,081,545 shares, compared to its average volume of 1,473,417. The stock has a market cap of $221.62 billion, a price-to-earnings ratio of 37.62, a PEG ratio of 2.43 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 1 year low of $415.60 and a 1 year high of $603.82. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. The business has a fifty day moving average of $565.87 and a 200 day moving average of $520.64.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, beating the consensus estimate of $5.64 by $0.03. The company had revenue of $10.89 billion for the quarter, compared to analyst estimates of $10.73 billion. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The firm’s revenue was down 4.9% on a year-over-year basis. During the same period in the prior year, the firm posted $5.40 earnings per share. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, April 15th. Stockholders of record on Friday, March 15th will be given a dividend of $0.39 per share. The ex-dividend date of this dividend is Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.10%.

Wall Street Analyst Weigh In

Several research analysts have weighed in on the stock. HSBC assumed coverage on shares of Thermo Fisher Scientific in a research note on Monday, December 18th. They set a “buy” rating and a $610.00 target price for the company. Barclays cut shares of Thermo Fisher Scientific from an “overweight” rating to an “equal weight” rating and increased their price target for the stock from $475.00 to $555.00 in a research report on Wednesday, January 24th. Royal Bank of Canada increased their price target on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the stock an “outperform” rating in a research report on Thursday, February 1st. Sanford C. Bernstein reissued a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Finally, Citigroup assumed coverage on shares of Thermo Fisher Scientific in a research report on Monday, March 18th. They set a “neutral” rating and a $620.00 price target on the stock. Five research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $599.00.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.